Effect of time interval from diagnosis to treatment for cervical cancer on survival: A nationwide cohort study

PLoS One. 2019 Sep 4;14(9):e0221946. doi: 10.1371/journal.pone.0221946. eCollection 2019.

Abstract

Objectives: Despite the ease of health care access and the waiver of copayments for cancer patients, treatment is delayed in a small proportion of Taiwanese patients diagnosed with cervical cancer. In this study, we explored the relationship between the time interval from diagnosis to treatment and survival in cervical cancer patients.

Material and methods: The study was a retrospective population-based observational study conducted between 2004 and 2010. In Taiwan, 12,020 patients were newly diagnosed with cervical cancer from 2004 to 2010, and 9,693 patients (80.6%) were enrolled in our final analysis.

Results: Most of the patients received treatment within 90 days of diagnosis (n = 9,341, 96.37%). After adjustment for other variables, patients who received treatment between 90 and 180 days and >180 days after diagnosis had a 1.33 (95% CI: 1.02-1.72, P < 0.05) and 1.36 (95% CI: 1.12-1.65, P < 0.05) times higher risk of death, respectively, than those who received treatment within 90 days. Kaplan-Meier analysis showed that the patients treated after 90 days from diagnosis had a lower overall survival rate than those treated within 90 days. In analysis stratifying the patients according to their initial tumor stage, namely stages I and II and stage III and IV, the time interval from diagnosis to treatment remained a significant prognosticator in those who received treatment >180 days after diagnosis.

Conclusion: A longer interval between diagnosis and treatment is associated with poorer prognosis among cervical cancer patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cohort Studies
  • Female
  • Humans
  • Middle Aged
  • Retrospective Studies
  • Survival Analysis
  • Taiwan / epidemiology
  • Time Factors
  • Uterine Cervical Neoplasms / diagnosis*
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / therapy*

Grants and funding

This study was supported by the grants from Asia University, China Medical University (CMU106-ASIA-13), and the Ministry of Science and Technology (MOST 104-2410-H-039 -002), Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.